二甲双胍治疗2型糖尿病的药物基因组学研究进展  

Research on Metformin pharmacogenomics in the treatment of type 2 diabetes

作　　者：张思敏[1] 韩学尧[1] 纪立农[1] 

机构地区：[1]北京大学人民医院内分泌科,100044

出　　处：《中国糖尿病杂志》2017年第8期760-764,共5页Chinese Journal of Diabetes

摘　　要：二甲双胍作为糖尿病一线治疗用药,使用广泛。但在实际临床使用中,二甲双胍的疗效和不良反应均存在个体差异,这可能与患者的遗传背景有关。研究参与二甲双胍的吸收、转运、摄取、排泄过程的相关基因多态性,与药物代谢和疗效多样性之间关系的药物基因组学,成为目前研究的热点。药物基因组学也是精准医学的理论基础之一。本文就二甲双胍治疗T2DM的药物基因组学研究进展进行文献综述。Metformin is a first-line therapy for type 2 diabetes mellitus. Individual variation in response to metformin exists in clinical practice, which is associated with genetic background. Current researches focus on elucidating the relationship between the polymorphisms of genes and the absorption, transportation, metabolism, and excretion of metformin, and also pharmacogenomics of metformin treatment. Pharmacogenomics also provides theoretical basis for individualized therapy. Here,we reviewed the literature progress for metformin pharmacogenomics.

关 键 词：二甲双胍 糖尿病 2型 药物基因组学 

分 类 号：R587.1[医药卫生—内分泌]